中文Vientiane, Laos - July 14, 2024 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer treatments, today announced that Adagrasibm have been approved by the Ministry of Health of Laos.
Approved drugs are:
Adagrasib: sold under the brand name ADADX. Adagrasib, a KRAS G12C inhibitor, irreversibly and selectively binds KRAS G12C, locking it in its inactive state. Similar to sotorasib, adagrasib is a selective covalent inhibitor of KRASG12C; however, reported pharmacologic differences in the molecules are the drug half-life of 5 hours for sotorasib as compared with 23 hours for adagrasib, dose-dependent extended exposure with adagrasib, and potential CNS penetration of adagrasib.
Adagrasib is a prescription medicine used to treat KRAS G12C–mutated ocally advanced or metastatic non–small cell lung cancer (NSCLC) or metastatic colorectal cancer (CRC)
Lao registered trade name: Lao Reg No.: 06L1128/24
About BigBear Pharmaceuticals:
BigBear Pharmaceuticals is headquartered in Vientiane, the capital of Laos. The company is committed to drug research and development, production and sales, providing high-quality, safe and effective pharmaceutical products. BigBear Pharmaceuticals has established a good reputation in the Lao drug market with its excellent professional knowledge and innovation capabilities, and actively participates in international pharmaceutical cooperation and exchanges.
Forward-Looking Statements:
Within the scope of applicable laws and regulations, "plans," "goals," "expectations," "forecasts" and other similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that could differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulatory and/or economic conditions, uncertainties in clinical study results, exposure to various market risks and other factors beyond the Company's control.